More HER2-discordant patients were found in ER-negative and TNBC tumors after adjusting for clinicopathological parameters, indicating the possible crucial role of the ER signaling pathway in influencing HER2-Low breast cancer [35,36,37]. Here, ESR1 is linked to breast cancer.